The Lancet Neurology has joined Bluesky!.🦋Find and follow us at 🌐And, of course, online at

In their Review, Valentina Serpieri, Fulvio D'Abrusco, and Enza Maria Valente discuss the relevance of primary cilia in neurological disorders. Read the paper at:

PODCAST: In this episode, host Laura Hart chats with Professor Amit Bar-Or (University of Pennsylvania) about the potential of the BTK inhibitor fenebrutinib in treating relapsing multiple sclerosis, highlighting future challenges in MS research.

"The overarching goal is to build a robust, transparent, and scalable framework to support the development of Parkinson’s disease treatments." Read more at:

Read the latest content on stroke rehabilitation, relapsing multiple sclerosis, acute-onset axonal neuropathy, α-synuclein biomarker assays, movement disorders, and more at

Are you ready for your research to spark global conversation? ✨ Begin your publication journey with us today and help to advance health and science worldwide.

Congratulations to our authors and peer reviewers, whose expertise and hard work enable us to continuously publish some of the best science for better lives. This is as much your achievement!

We are the world-leading clinical neurology journal. While a partial measurement of our impact, we are pleased to share our Impact Factor of 45·5 and CiteScore of 62·6.

Shorena Janelidze and colleagues report on a longitudinal cohort study looking at which plasma biomarkers most accurately predict longitudinal changes in Alzheimer's disease-related pathology and cognitive functioning in individuals with Down syndrome

In a longitudinal cohort study, Christina D Orrú et al. assess the diagnostic and prognostic value of quantitative CSF α-synuclein SAA kinetic measures in Parkinson's disease:

Xia Wang and colleagues assessed early intensive BP-lowering treatment and its dependence on timing in patients with intracerebral haemorrhage in a pooled analysis of the Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trials.

“Friedreich’s ataxia is a complex disease with diverse symptoms that our current understanding of the underlying genetic mutation fails to fully explain.” Read more at:

PODCAST: Sarah Passey and Marte-Helene Bjørk discuss the latest evidence and practical guidance on managing reproductive risks in people with epilepsy

NEW ISSUE: Read the latest content on acute intracerebral haemorrhage, Parkinson's disease, Down syndrome, epilepsy, and Friedrich's ataxia at: .

PODCAST: Sam Griffiths is joined by Geoff Manley to discuss the new NIH-NINDS classification of acute TBI and what it means for the future of TBI research and patient care.

NEW ISSUE: Read the latest content on ischaemic stroke and transient ischaemic attack, amyotrophic lateral sclerosis, traumatic brain injury, Alzheimer's disease, CSF transport, Parkinson's disease and more at:

These questions will be addressed in ongoing studies in DIAD (the DIAN-TU Amyloid Removal Trial), and in ongoing late-onset prevention trials.

These findings, although clinically meaningful, are statistically uncertain and thus further research is needed to clarify the extent to which complete amyloid removal can delay, slow, or prevent Alzheimer's disease dementia.

Findings suggest that substantial amyloid plaque removal in presymptomatic DIAD mutation carriers might delay and slow the onset and disease progression in those treated for a long time (average of 8 years), many years before symptom onset.

In an open-label extension of the phase 2/3 randomised, placebo-controlled platform DIAN-TU trial, Randall Bateman and colleagues assess the safety and efficacy of long-term treatment with high doses of gantenerumab in participants with dominantly inherited Alzheimer's disease.

PODCAST: Laura Hart (Deputy Editor) chats to Marialuisa Gandolfi (University of Verona in Italy) about advances in the classification and management of pain in Parkinson’s disease @MarialuisaGand